Literature DB >> 12244145

Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation.

Hiroyuki Matsue1, Chendong Yang, Keiko Matsue, Dale Edelbaum, Mark Mummert, Akira Takashima.   

Abstract

Rapamycin (RAP), tacrolimus (FK506), cyclosporin A, and glucocorticoids represent modern and classic immunosuppressive agents being used clinically. Although these agents have distinct molecular mechanisms of action and exhibit different immunoregulatory profiles, their direct influences on Ag presentation processes remain relatively unknown. Here we report quantitative and qualitative differences among the above four immunosuppressants in their impact on Ag-specific, bidirectional interaction between dendritic cells (DC) and CD4(+) T cells. In the presence of relevant Ag, bone marrow-derived DC delivered activation signals to CD4(+) T cells isolated from the DO11.10 TCR transgenic mice, leading to clonal expansion; secretion of IFN-gamma, IL-2, and IL-4; and surface expression of CD69. Conversely, DO11.10 T cells delivered maturation signals to DC, leading to IL-6 and IL-12 production and CD40 up-regulation. FK506 (10(-10)-10(-8) M) and cyclosporin A (10(-9)-10(-7) M) each blocked efficiently and uniformly all the changes resulting from intercellular signaling in both DC-->T cell and T cell-->DC directions. Dexamethasone (10(-9)-10(-6) M) suppressed all changes, except for CD69 up-regulation, rather incompletely. Remarkably, RAP (10(-10)-10(-8) M) efficiently inhibited DC-induced T cell proliferation and T cell-mediated CD40 up-regulation by DC without abrogating other changes. Interestingly, T cell-independent DC maturation triggered by LPS stimulation was inhibited by dexamethasone, but not by other agents. Our results demonstrate contrasting pharmacological effects of RAP vs calcineurin inhibitors on Ag presentation, thus forming a conceptual framework for rationale-based selection (and combination) of immunosuppressive agents for clinical application.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244145     DOI: 10.4049/jimmunol.169.7.3555

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

2.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 3.  Functional diversity and plasticity of human dendritic cell subsets.

Authors:  Tomoki Ito; Yong-Jun Liu; Norimitsu Kadowaki
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

4.  Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion.

Authors:  Mar Naranjo-Gómez; Nuria Climent; Joan Cos; Harold Oliva; Margarita Bofill; José M Gatell; Teresa Gallart; Ricardo Pujol-Borrell; Francesc E Borràs
Journal:  Immunology       Date:  2006-08-24       Impact factor: 7.397

5.  Discovery of novel immunostimulants by dendritic-cell-based functional screening.

Authors:  Norikatsu Mizumoto; Jimin Gao; Hironori Matsushima; Yasushi Ogawa; Hiroaki Tanaka; Akira Takashima
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

6.  Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

Authors:  Luisa Giaccone; Jeannine S McCune; Michael B Maris; Theodore A Gooley; Brenda M Sandmaier; John T Slattery; Scott Cole; Richard A Nash; Rainer F Storb; George E Georges
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

7.  Rapamycin unbalances the polarization of human macrophages to M1.

Authors:  Alessia Mercalli; Ines Calavita; Erica Dugnani; Antonio Citro; Elisa Cantarelli; Rita Nano; Raffaella Melzi; Paola Maffi; Antonio Secchi; Valeria Sordi; Lorenzo Piemonti
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

8.  Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.

Authors:  Hiroaki Tanaka; Hironori Matsushima; Norikatsu Mizumoto; Akira Takashima
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

9.  Rapamycin modulates the maturation of rat bone marrow-derived dendritic cells.

Authors:  Yingjun Ding; Xiang Cheng; Tingting Tang; Rui Yao; Yong Chen; Jiangjiao Xie; Xian Yu; Yuhua Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

10.  Identification of crassin acetate as a new immunosuppressant triggering heme oxygenase-1 expression in dendritic cells.

Authors:  Hironori Matsushima; Hiroaki Tanaka; Norikatsu Mizumoto; Akira Takashima
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.